Bupropion for weight reduction

Kishore M. Gadde, Glen Xiong

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Bupropion is a norepinephrine and dopamine uptake inhibitor that has been available for several years for the treatment of depression and aiding smokers to quit. Although bupropion is not approved for treating obesity, three randomized clinical trials have shown some degree of efficacy for this drug in promoting weight loss in obese patients. The present drug profile provides a review of the pharmacology of bupropion, clinical evidence of efficacy with regard to weight reduction, tolerability and risks, and the current and future role of this drug in the management of obesity.

Original languageEnglish (US)
Pages (from-to)17-24
Number of pages8
JournalExpert Review of Neurotherapeutics
Volume7
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Bupropion
Weight Loss
Obesity
Dopamine Uptake Inhibitors
Pharmaceutical Preparations
Norepinephrine
Randomized Controlled Trials
Pharmacology
Therapeutics

Keywords

  • Antiobesity drugs
  • Bupropion
  • Obesity
  • Weight loss

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Bupropion for weight reduction. / Gadde, Kishore M.; Xiong, Glen.

In: Expert Review of Neurotherapeutics, Vol. 7, No. 1, 01.2007, p. 17-24.

Research output: Contribution to journalArticle

Gadde, Kishore M. ; Xiong, Glen. / Bupropion for weight reduction. In: Expert Review of Neurotherapeutics. 2007 ; Vol. 7, No. 1. pp. 17-24.
@article{88f45c3ddf3b445fbfe69ee04c43aa2a,
title = "Bupropion for weight reduction",
abstract = "Bupropion is a norepinephrine and dopamine uptake inhibitor that has been available for several years for the treatment of depression and aiding smokers to quit. Although bupropion is not approved for treating obesity, three randomized clinical trials have shown some degree of efficacy for this drug in promoting weight loss in obese patients. The present drug profile provides a review of the pharmacology of bupropion, clinical evidence of efficacy with regard to weight reduction, tolerability and risks, and the current and future role of this drug in the management of obesity.",
keywords = "Antiobesity drugs, Bupropion, Obesity, Weight loss",
author = "Gadde, {Kishore M.} and Glen Xiong",
year = "2007",
month = "1",
doi = "10.1586/14737175.7.1.17",
language = "English (US)",
volume = "7",
pages = "17--24",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Bupropion for weight reduction

AU - Gadde, Kishore M.

AU - Xiong, Glen

PY - 2007/1

Y1 - 2007/1

N2 - Bupropion is a norepinephrine and dopamine uptake inhibitor that has been available for several years for the treatment of depression and aiding smokers to quit. Although bupropion is not approved for treating obesity, three randomized clinical trials have shown some degree of efficacy for this drug in promoting weight loss in obese patients. The present drug profile provides a review of the pharmacology of bupropion, clinical evidence of efficacy with regard to weight reduction, tolerability and risks, and the current and future role of this drug in the management of obesity.

AB - Bupropion is a norepinephrine and dopamine uptake inhibitor that has been available for several years for the treatment of depression and aiding smokers to quit. Although bupropion is not approved for treating obesity, three randomized clinical trials have shown some degree of efficacy for this drug in promoting weight loss in obese patients. The present drug profile provides a review of the pharmacology of bupropion, clinical evidence of efficacy with regard to weight reduction, tolerability and risks, and the current and future role of this drug in the management of obesity.

KW - Antiobesity drugs

KW - Bupropion

KW - Obesity

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=33846216855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846216855&partnerID=8YFLogxK

U2 - 10.1586/14737175.7.1.17

DO - 10.1586/14737175.7.1.17

M3 - Article

C2 - 17187492

AN - SCOPUS:33846216855

VL - 7

SP - 17

EP - 24

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 1

ER -